Drug Safety

, Volume 34, Issue 3, pp 199–210

Safety of Nortriptyline at Equivalent Therapeutic Doses for Smoking Cessation

A Systematic Review and Meta-Analysis
  • Teerapon Dhippayom
  • Nathorn Chaiyakunapruk
  • Thitima Jongchansittho
Original Research Article

DOI: 10.2165/11585950-000000000-00000

Cite this article as:
Dhippayom, T., Chaiyakunapruk, N. & Jongchansittho, T. Drug-Safety (2011) 34: 199. doi:10.2165/11585950-000000000-00000

Abstract

Background: The limited use of nortriptyline for smoking cessation is likely due to concerns about its serious adverse effects.

Objective: To examine the safety of nortriptyline at doses equivalent to those used in aiding smoking cessation.

Data Sources: A systematic search of relevant articles in MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, CINAHL, PsychINFO, WHO publications and the Clinical Trials database (through November 2008).

Study Selection: All studies of nortriptyline at doses between 75 and 100 mg in any indication were reviewed.

Data Extraction: The quality of included studies was assessed based on the Jadad score. Data were extracted using a data extraction form.

Data Synthesis: From 442 potentially relevant articles identified, 17 studies met our selection criteria and were included for data analysis. Indications for nortriptyline in these studies were smoking cessation (eight studies), depression (five studies), neuropathic pain (three studies) and schizophrenia (one study). 2885 individuals participated in these studies, with exposure time ranging between 4 and 12 weeks. The major comparator used in these trials was placebo. Overall, no life-threatening events occurred in these studies. Orthostatic hypotension was significantly higher in nortriptyline users than in comparator groups (relative risk 2.8; 95% CI 1.4, 5.3). Other adverse events significantly associated with nortriptyline were anticholinergic-related effects including drowsiness, dizziness, gastrointestinal disturbance and dysgeusia.

Conclusions: Current evidence suggests that nortriptyline, at doses between 75 and 100 mg, is not significantly associated with serious adverse events when administered in patients without underlying cardiovascular disease.

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Teerapon Dhippayom
    • 1
  • Nathorn Chaiyakunapruk
    • 1
    • 2
    • 3
    • 4
  • Thitima Jongchansittho
    • 5
  1. 1.Pharmaceutical Care Research Unit, Faculty of Pharmaceutical SciencesNaresuan UniversityPhitsanulokThailand
  2. 2.Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy PracticeFaculty of Pharmaceutical Sciences, Naresuan UniversityPhitsanulokThailand
  3. 3.School of Population HealthUniversity of QueenslandBrisbaneAustralia
  4. 4.School of PharmacyUniversity of Wisconsin-MadisonMadisonUSA
  5. 5.Charoenkrung Pracharak HospitalBangkokThailand